These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32252973)

  • 21. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct oral anticoagulants: a guide for daily practice.
    Fontana P; Robert-Ebadi H; Bounameaux H; Boehlen F; Righini M
    Swiss Med Wkly; 2016; 146():w14286. PubMed ID: 26964028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Italian intersociety consensus on DOAC use in internal medicine.
    Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
    Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
    Dülgeroglu J; Schmidt D
    Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
    [No Abstract]   [Full Text] [Related]  

  • 27. [Novel oral anticoagulants--issues in clinical practice].
    Hohmann C; Neumann-Haefelin T; Radziwill R; Benöhr P
    Med Monatsschr Pharm; 2015 Oct; 38(10):374-85; quiz 387-8. PubMed ID: 26731855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What role for the direct oral anticoagulants in oncology?].
    Lebellec L; Kouakam C; Bertrand N; Penel N
    Bull Cancer; 2018; 105(7-8):631-633. PubMed ID: 29960639
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
    Stebler-Fontaine L; Rossel A; Marti C; Righini M; Robert-Ebadi H
    Rev Med Suisse; 2019 Dec; 15(674):2232-2235. PubMed ID: 31804034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
    Nakamura M; Yamada N; Ito M
    J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [From heparin to apixaban: anticoagulants cut both ways?].
    Hartung K; Meyer F; Bock F; Isermann B
    Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
    Papadopoulos DV; Kostas-Agnantis I; Gkiatas I; Tsantes AG; Ziara P; Korompilias AV
    Eur J Orthop Surg Traumatol; 2017 Jul; 27(5):573-582. PubMed ID: 28314985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
    Ravikumar R; Lim CS; Davies AH
    Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
    Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
    Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?].
    Debourdeau P; Cossou-Gbeto C; Takam-Sohwe T; Laroche JP
    Bull Cancer; 2020 Feb; 107(2):224-233. PubMed ID: 32005356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticoagulants: What is new and what is the standard?
    Lesko LJ
    Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
    Bass AR
    Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
    Kimpton M; Carrier M
    Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.